Featured Research

from universities, journals, and other organizations

'Humanized' mice enable malaria research breakthrough

Date:
September 10, 2012
Source:
Oregon Health & Science University
Summary:
A novel human liver-chimeric mouse model has made possible a research breakthrough that will greatly accelerate studies of the most lethal forms of human malaria.

A maturing Plasmodium falciparum liver stage parasite in the liver of the human liver-chimeric FRGTM KO. Membranes of the developing merozoites are shown in red, DNA in blue, and the human hepatocytes within the liver-chimeric FRGTM KO mouse are shown in green.
Credit: Seattle Biomedical Research Institute

A novel human liver-chimeric mouse model developed at Oregon Health & Science University and Yecuris Corporation has made possible a research breakthrough at Seattle Biomedical Research Institute that will greatly accelerate studies of the most lethal forms of human malaria.

Related Articles


The study findings are published online in the Journal of Clinical Investigation. Study photos were selected to appear in "Scientific Show Stoppers" on the JCI blog.

Plasmodium falciparum, one of two human-specific malaria parasites, is a global health crisis, causing more than 216 million new infections annually and resulting in an estimated 655,000 deaths, according to the World Health Organization.

Sporozoites, the infectious form of the parasite, are spread to people through the bites of infected mosquitos and multiply in the human liver during the initial stages of infection. There, they undergo liver stage development, culminating in the formation and release of tens of thousands of merozoites, the parasitic phase of development that infects red blood cells.

Until now, there have been few data on human malaria liver stage biology due to the lack of a viable small animal model and because liver stage P. falciparum does not grow well in a dish. Consequently, most research and therapeutics to date have targeted the human blood stage of P. falciparum's development because it replicates well in culture.

The liver-to-blood stage of P. falciparum is the focus of this research because the parasite is virtually harmless, causing no disease symptoms, prior to its transition to the blood stage.

In this study, researchers at Seattle Biomedical Research Institute, Yecuris Corporation, Oregon Health & Science University and The Rockefeller University have demonstrated that a complete liver-to-blood stage infection of P. falciparum is possible using a unique immunocompromised mouse model engrafted with human liver-chimeric cells.

The mouse model, termed the FRGTM KO mouse, was developed by paper co-author and internationally accomplished stem cell researcher Markus Grompe, M.D., in the Papé Family Pediatric Research Institute, a research arm of Oregon Health & Science University Doernbecher Children's Hospital.

In 2007 the technology was licensed to Yecuris Corporation, a biotechnology company that now produces the model and human hepatocytes on a commercial scale. As a result of this work, the FRGTM KO mouse now will be used to study new drug interventions, parasite attenuation and innate immune responses to P. falciparum liver stage infection.

The scientists also report that through the infection of the FRGTM KO mouse model, they were able to observe a previously unknown expression of proteins in liver stage development in humans that may be exploited for intervention. Equally important, they say, the FRGTM KO mouse could well provide unique opportunities for the study of another severe form of human malaria, Plasmodium vivax.

"These breakthroughs are remarkable and highlight OHSU and Yecuris' contributions to local biotechnology and research breakthroughs globally. The next generation mouse model we're developing will have a human immune system that will allow us to test not just drugs, but vaccines, which has never been done for parasitic diseases," said Grompe, Ray Hickey Chair and Director of the Papé Family Pediatric Research Institute, OHSU Doernbecher Children's Hospital; and professor of pediatrics, and molecular and medical genetics, OHSU School of Medicine.

Grompe founded Yecuris Corporation in 2007 and is a shareholder. John Bial, who joined Yecuris in 2009, is president and chief executive officer.

"The extensive collaborative relationships and risk-taking involved in planning and executing this research is a testament to the tireless dedication of these teams to solving one of the globe's oldest killers. It also highlights how private and public funding can come together effectively to address critical challenges in global health," said Bial.

"This first demonstration of the newly developed dual humanized FRGTM KO system is a good introduction to the kinds of translational medicine benefits that we can expect to see from these technologies. We anticipate that the next frontier for these systems will be as platforms for human vaccine development and validation, which may very likely first be tested in the area of malaria," Bial explained.

Investigators who contributed to this work include: Stefan Kappe, Ashley Vaughan, Sebastian Mikolajczak, Alexis Kaushansky, Nelly Camargo, Seattle Biomedical Research Institute; Elizabeth Wilson, John Bial, Yecuris Corporation; Markus Grompe, Papé Family Pediatric Research Institute, Oregon Stem Cell Center, Oregon Health & Science University, Doernbecher Children's Hospital; and Alexander Ploss, Center for the Study of Hepatitis C, The Rockefeller University.

Today's JCI study, "Complete Plasmodium falciparum liver stage development in liver-chimeric mice," was funded by grants to the Seattle Biomedical Research Institute from the Bill and Melinda Gates Foundation (OPP1016829) and the Department of Defense (W81XWH?11?2?0184).

The Oregon Health & Science University research leading to the development of the FRGTM KO mouse was funded by the National Institutes of Health and the The Oregon Opportunity fund.


Story Source:

The above story is based on materials provided by Oregon Health & Science University. Note: Materials may be edited for content and length.


Cite This Page:

Oregon Health & Science University. "'Humanized' mice enable malaria research breakthrough." ScienceDaily. ScienceDaily, 10 September 2012. <www.sciencedaily.com/releases/2012/09/120910161554.htm>.
Oregon Health & Science University. (2012, September 10). 'Humanized' mice enable malaria research breakthrough. ScienceDaily. Retrieved October 31, 2014 from www.sciencedaily.com/releases/2012/09/120910161554.htm
Oregon Health & Science University. "'Humanized' mice enable malaria research breakthrough." ScienceDaily. www.sciencedaily.com/releases/2012/09/120910161554.htm (accessed October 31, 2014).

Share This



More Plants & Animals News

Friday, October 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Watch Baby Goose Survive A 400-Foot Cliff Dive

Watch Baby Goose Survive A 400-Foot Cliff Dive

Buzz60 (Oct. 31, 2014) — For its nature series Life Story, the BBC profiled the barnacle goose, whose chicks must make a daredevil 400-foot cliff dive from their nests to find food. Jen Markham has the astonishing video. Video provided by Buzz60
Powered by NewsLook.com
World's Salamanders At Risk From Flesh-Eating Fungus

World's Salamanders At Risk From Flesh-Eating Fungus

Newsy (Oct. 31, 2014) — The import of salamanders around the globe is thought to be contributing to the spread of a deadly fungus. Video provided by Newsy
Powered by NewsLook.com
Alcoholic Drinks In The E.U. Could Get Calorie Labels

Alcoholic Drinks In The E.U. Could Get Calorie Labels

Newsy (Oct. 31, 2014) — A health group in the United Kingdom has called for mandatory calorie labels on alcoholic beverages in the European Union. Video provided by Newsy
Powered by NewsLook.com
Malaria Threat in Liberia as Fight Against Ebola Rages

Malaria Threat in Liberia as Fight Against Ebola Rages

AFP (Oct. 31, 2014) — Focus on treating the Ebola epidemic in Liberia means that treatment for malaria, itself a killer, is hard to come by. MSF are now undertaking the mass distribution of antimalarials in Monrovia. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Plants & Animals

Earth & Climate

Fossils & Ruins

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins